Endotoxin Removal from Bench to Process Scale

Endotoxin or lipopolysaccharides (LPS) are highly toxic components of the cell wall of Gram-negative bacteria and are often present in significant amounts in bacterial cell expression systems such as E.coli.

A number of methods have been adopted for the removal of endotoxin based on adsorption, in particular ion exchange chromatography. Although downstream processing can significantly reduce endotoxin levels in the product, efficient and cost effective removal of residual endotoxin from biopharmaceutical preparations remains a challenge.

Astrea Bioseparations Ltd. ('Astrea') has developed a novel affinity chromatography adsorbent, EtoxiClear, that is highly stable, robust and non-toxic, with a high affinity for bacterial endotoxin and low protein binding. EtoxiClear is a cost effective and scalable technology designed for use in endotoxin removal applications including process development, sample/buffer preparation and product polishing steps used during cGMP manufacture of biological molecules.

This application note describes the use of EtoxiClear to effectively remove endotoxin from a purified immunoglobulin protein solution at both bench scale and process scale; utilising Astrea’s new 100 mm diameter Evolve Process Column.


A purified immunoglobulin solution (~12 mg/mL) was determined to have an endotoxin burden. As a result, both a 5 mL column and a 780 mL Evolve™ Process Column were packed with EtoxiClear™, using the guidelines in Table 1, to demonstrate high endotoxin clearance at different process scales. Prior to application the columns were depyrogenated for 16 hours using 0.5 M sodium hydroxide (NaOH). The NaOH was removed using ~1 column volume (CV) of water for injection (WFI) followed by equilibration buffer. Then 2 CV of the purified immunoglobulin solution was loaded onto each column and the non-bound fraction collected. 



EtoxiClear provides an immunoglobulin protein recovery of >96% for the 5 mL column (bench scale) and >99% recovery using the 780 mL column (100 mm diameter Evolve™ Process Column). There is a 3 log removal of endotoxin to obtain <1 EU/mL in the non-bound fraction, with less than 0.1 EU/mg protein for the Evolve™ Process Column.

As a result, EtoxiClear shows high performance and scalability for endotoxin clearance with low protein binding at both bench and process scale. The Evolve Process Column is well suited for EtoxiClear endotoxin removal applications and with the option to purchase a dedicated refresh kit to replace all the wetted parts of the column (including the acrylic tube), this column range provides significant cost savings whilst eliminating the need to prove endotoxin clearance from previous product and cleaning validation.

Click here to subscribe to our mailing list and ensure you always receive the latest updates and exclusive offers from Astrea Bioseparations.


Astrea Bioseparations Ltd
Horizon Park, Barton Road, Comberton
Cambridge, CB23 7AJ, UK.

Tel: +44 (0) 1223 420300
Email: [email protected]

EtoxiClear Astrea Bioseparations Ltd and the Astrea logo are trademarks of Astrea Bioseparations Ltd. PuraBead® is registered with the U.S. Patent and Trademark Office.

PuraBead® - this product or portions thereof is manufactured and sold under licence from GE Healthcare under US patents 6841097 and 7341202 and any corresponding patents for life sciences research and the purification/separation of naturally occurring or recombinant plasma derived proteins.

Copyright © 2020 Astrea Bioseparations Ltd.


About the Author

An experienced Sales Director with over 30 years’ experience in the biotech and life sciences sectors, specialising in bioprocessing and bioseparation techniques with degree level Biochemistry from the University of West London. Having started my career working in a research and development laboratory, I have progressed into consultative sales roles for capital high-tech equipment and strategic account management, leveraging my lab experience for large pharmaceutical companies such as GE. I have been with Astrea Bioseparations ('Astrea') since September 2013 with responsibilities covering the global sales and marketing of its products and services. Since joining Astrea, I have been instrumental in developing the product pipeline by successfully launching the ever-growing Evolve and EvolveD column ranges into Astrea’s offering

Follow on Linkedin More Content by Taylor Hayward
Previous Article
Capture and purification of recombinant albumin-fusion proteins using AlbuPure®
Capture and purification of recombinant albumin-fusion proteins using AlbuPure®

AlbuPure® can be used to capture and purify recombinant albumin-fusion proteins from cell culture supernata...

Next Article
Immobilised Boronate Ligand Affinity Adsorbents for Glycoproteins
Immobilised Boronate Ligand Affinity Adsorbents for Glycoproteins

Review useful insights and data highlighting the importance of protein glycosylation in Biopharmaceuticals.

If you found this article useful, why not contact us to arrange a technical presentation?

Contact Us